Pomerantz received his undergraduate degree from Yale University and his medical degree from Stanford University. Pomerantz received his post-doctoral training in cancer genetics with Dr.
Pomerantz's research focuses on the factors associated with cancer risk, with an emphasis on prostate cancer. Prostate cancer develops in the setting of many environmental and inherited risk factors.
Since , the inherited component of the disease has come into clearer focus. Multiple genetic markers, inherited from one's parents and highly associated with risk of prostate cancer, have been discovered. However, the mechanism in which these inherited factors predispose one to disease is unknown.
Working closely with clinicians, biostatisticians and epidemiologists at Dana-Farber and the Broad Institute, he is actively deciphering this mechanism in an attempt to define the underpinnings of prostate cancer risk.
Insulin resistance during androgen deprivation therapy in men with prostate cancer. View in: Pubmed. Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma. Cell Rep. Cancer Immunol Res. Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37, cases. Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.
